The FDA announced early January that under its modified Mifepristone REMS Program, patients will be able to acquire Mifeprex — and its approved generic — at retail pharmacies.
New abortion pill rules challenge Catholics to reimagine effective pro-life outreach
FDA permits retail pharmacies to dispense abortion drugs, prompting criticism from Catholic, pro-life groups
The U.S. Food and Drug Administration will allow retail pharmacies to offer abortion pills in the United States for the first time, the agency announced Jan. 3, prompting criticism from Catholic and pro-life groups.
FDA decision on medical abortion puts women’s lives, health at risk, says bishops’ pro-life chair
By no longer requiring the abortion drug mifepristone to be picked up in person, the U.S. Food and Drug Administration is “merely succumbing to the abortion industry’s pressure to loosen safety standards,” instead of protecting the lives and health of mothers and children as it should do, he said.
FDA criticized for lifting in-person requirement to receive abortion drug
The decision by the acting commissioner of the U.S. Food and Drug Administration to suspend enforcement of the agency’s in-person prescribing requirement for the abortion drug endangers women’s health and possibly their lives, pro-life leaders said.